In this issue of Cardiovascular Revascularization Medicine, Bangalore et al. present a pre-specified subgroup analysis of the TUXEDO-India trial. In the primary study results of this trial, the Taxus Element paclitaxel-eluting stent (PES) failed to meet the criteria for non-inferiority to the Xience Prime everolimus-eluting stent (EES) with respect to the primary composite endpoint of target vessel failure (TVF) at 1 year. In fact, the PES had significantly higher rates of TVF, target-vessel myocardial infarction (TV MI), stent thrombosis, and target lesion revascularization (TLR). The objective for this subgroup analysis was to test for homogeneity of the treatment effect for EES versus PES in subjects with or without chronic kidney disease (CKD), defined as estimated glomerular filtration rate < 60 ml/min/1.73 m ² .